Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) traded up 5.1% during mid-day trading on Monday . The stock traded as high as $27.18 and last traded at $27.11. 382,875 shares were traded during mid-day trading, a decline of 78% from the average session volume of 1,740,483 shares. The stock had previously closed at $25.80.
Analyst Ratings Changes
Several research analysts have issued reports on the company. HC Wainwright raised Cassava Sciences from a "neutral" rating to a "buy" rating and set a $116.00 price target on the stock in a report on Tuesday, October 8th. Rodman & Renshaw restated a "buy" rating and issued a $107.00 target price on shares of Cassava Sciences in a report on Thursday, August 8th.
View Our Latest Stock Report on Cassava Sciences
Cassava Sciences Trading Up 6.6 %
The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -12.69 and a beta of -0.63. The stock has a 50-day simple moving average of $28.16 and a 200 day simple moving average of $22.24.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.57. During the same period last year, the business earned ($0.63) EPS. Sell-side analysts expect that Cassava Sciences, Inc. will post -5.7 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cassava Sciences
Institutional investors have recently made changes to their positions in the company. EntryPoint Capital LLC lifted its holdings in shares of Cassava Sciences by 1,251.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,297 shares of the company's stock valued at $47,000 after buying an additional 2,127 shares during the last quarter. Creative Planning acquired a new stake in shares of Cassava Sciences during the 3rd quarter valued at about $201,000. NBC Securities Inc. lifted its holdings in shares of Cassava Sciences by 9.3% during the 1st quarter. NBC Securities Inc. now owns 7,650 shares of the company's stock valued at $155,000 after buying an additional 650 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Cassava Sciences by 146.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company's stock valued at $191,000 after buying an additional 5,594 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new position in shares of Cassava Sciences in the 2nd quarter valued at approximately $131,000. 38.05% of the stock is currently owned by institutional investors and hedge funds.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
